Welcome to our dedicated page for Kenvue news (Ticker: KVUE), a resource for investors and traders seeking the latest updates and insights on Kenvue stock.
Kenvue Inc. (NYSE: KVUE) is described as the world’s largest pure-play consumer health company by revenue, with a portfolio of science-backed brands such as Aveeno®, BAND-AID® Brand, Johnson’s®, Listerine®, Neutrogena®, Tylenol® and Zyrtec®. This news page aggregates company announcements, press releases and market-moving updates related to KVUE stock and Kenvue’s global consumer health operations.
Readers can find earnings news, including quarterly results where Kenvue reports net sales trends, organic sales performance, gross profit and operating income margins, and diluted and adjusted earnings per share. These releases often include management commentary on operating priorities, productivity initiatives, supply chain optimization efforts and updated outlooks for the fiscal year, along with explanations of non-GAAP measures such as Adjusted gross profit margin, Adjusted operating income margin, Adjusted net income, Adjusted EBITDA margin, Adjusted effective tax rate, Free cash flow and Organic sales.
The feed also covers strategic and corporate developments. In 2025, Kenvue announced a comprehensive review of strategic alternatives, leadership changes including a CEO transition, and a definitive agreement under which Kimberly-Clark Corporation will acquire all outstanding shares of Kenvue common stock in a cash and stock transaction, as detailed in joint press releases and a Form 8-K. Updates on this planned acquisition, board decisions and related shareholder communications are key topics for investors following KVUE news.
Additional items include dividend declarations by Kenvue’s Board of Directors, highlighting the company’s approach to returning capital to shareholders, and partnership and innovation news, such as the collaboration with Albert Invent to apply AI to Kenvue’s research and development processes. Together, these categories give investors, analysts and consumers a consolidated view of how Kenvue manages its brand portfolio, financial performance and strategic direction. Bookmark this page to quickly access the latest official Kenvue updates relevant to KVUE stock.
Kimberly-Clark (NASDAQ: KMB) agreed to acquire Kenvue (NYSE: KVUE) in a cash-and-stock transaction valuing Kenvue at an enterprise value of approximately $48.7 billion (based on KMB close on Oct 31, 2025). The deal offers Kenvue shareholders $3.50 cash plus 0.14625 KMB shares (total $21.01 per KVUE share) and is expected to close in H2 2026, subject to approvals.
The combined company is projected to generate ~$32 billion revenue and ~$7 billion adjusted EBITDA in 2025, with anticipated run-rate synergies of $2.1 billion and $2.5 billion of one-time costs to capture them. Post-close ownership: ~54% KMB / 46% KVUE.
Kenvue (NYSE: KVUE) declared a quarterly cash dividend of $0.2075 per share. The dividend is payable on November 26, 2025 to shareholders of record as of the close of business on November 12, 2025. The announcement provides a dated cash return to shareholders and specifies payment and record dates.
Contact details for investor and media relations were provided.
Kenvue (NYSE: KVUE) will announce its third quarter 2025 financial results before the market opens on November 6, 2025.
The company will host a conference call and live webcast at 8:30 a.m. ET; U.S. dial-in 877-407-8835, international dial-in +1 201-689-8779. A replay will be available after the live event at investors.kenvue.com.
Contact details provided for investor and media relations. Kenvue is described as a global consumer health company with brands including Aveeno, BAND-AID Brand, Johnson’s, Listerine, Neutrogena, and Tylenol.
Albert Invent announced a strategic, multi-year partnership with Kenvue (NYSE: KVUE) to accelerate end-to-end R&D across Kenvue's global consumer health brands. The collaboration began in Q1 2025 and focuses on integrating Albert Invent's AI platform to digitalize workflows, unify data management, and automate hundreds of R&D processes.
Albert Invent's proprietary engine is trained on over 15 million molecular structures and is used by thousands of researchers in 30+ countries. The partnership aims to speed product development, improve quality control, and streamline regulatory compliance across Kenvue's brands.
Kenvue (NYSE: KVUE) reported challenging Q2 2025 results with declining performance across key metrics. Net sales decreased 4.0% year-over-year, with organic sales declining 4.2%. The company reported diluted EPS of $0.22 and adjusted diluted EPS of $0.29, down from $0.32 in the prior year.
Under new leadership, including Interim CEO Kirk Perry and CFO Amit Banati, Kenvue revised its FY2025 outlook downward, now expecting low-single-digit declines in net and organic sales, with adjusted diluted EPS projected at $1.00-$1.05. The company is advancing a comprehensive strategic alternatives review while implementing measures to accelerate profitable growth.
The performance decline was attributed to unfavorable value realization of 0.9%, volume decline of 3.3%, weak seasonal performance in North America, and trade inventory fluctuations. The company's gross profit margin contracted to 58.9% from 59.1% year-over-year.
Kenvue (NYSE: KVUE), the world's largest pure-play consumer health company, has announced a dividend increase. The company's Board of Directors declared a quarterly dividend of $0.2075 per share on its common stock, representing a 1.2% increase from the previous quarter.
The dividend will be payable on August 27, 2025, to shareholders of record as of August 13, 2025. Kenvue's portfolio includes well-known brands such as Aveeno, BAND-AID, Johnson's, Listerine, Neutrogena, and Tylenol.
Kenvue (NYSE: KVUE), the world's largest pure-play consumer health company, will release its Q2 2025 financial results before market open on August 7, 2025. The company will host a conference call and webcast at 8:30 a.m. ET to discuss the results.
Investors can access the conference call by dialing 877-407-8835 (U.S.) or +1 201-689-8779 (international). A live webcast will be available at investors.kenvue.com, with a replay accessible after the event.
Kenvue (NYSE:KVUE), the world's largest pure-play consumer health company, announced significant leadership changes and strategic initiatives. The company has appointed Kirk Perry as Interim CEO, replacing Thibaut Mongon, effective immediately. Perry brings over 30 years of consumer products and technology experience.
The Board has initiated a comprehensive strategic review to unlock shareholder value, considering portfolio optimization and operational improvements. Additionally, Kenvue released preliminary Q2 2025 results showing a 4.0% decline in net sales and organic sales decrease of 4.2%, with adjusted diluted EPS expected between $0.28 and $0.29.
The company will provide updated full-year 2025 guidance during its complete Q2 earnings release on August 7, 2025.FAQ
What is the current stock price of Kenvue (KVUE)?
What is the market cap of Kenvue (KVUE)?
